我們已在上線！ 進一步了解
AMLX圖示

Amylyx Pharmaceuticals
AMLX

26.34 USD
-1.31
4.74%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
26.34
0.00
0%
1天
-4.74%
5天
-6.06%
1個月
-19.28%
3個月
54.76%
6個月
48.56%
今年迄今
130.65%
1年
73.63%
5年
45.77%
10年
45.77%
 

關於： Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

員工： 136

醫療保健 藥品製造商－特殊及學名藥

新聞

正面
中性
負面
市場情緒 3個月
正面 41.9%
中性 51.6%
負面 6.5%
中性
Schaeffers Research
4 天前
11 Stocks Most Likely to See a Short Squeeze Rally
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
11 Stocks Most Likely to See a Short Squeeze Rally
中性
Business Wire
10 天前
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
正面
MarketBeat
14 天前
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
中性
Schaeffers Research
15 天前
10 Stocks With Massive Short Squeeze Potential
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?
10 Stocks With Massive Short Squeeze Potential
中性
Business Wire
23 天前
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum.
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
中性
Seeking Alpha
上個月
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
中性
Business Wire
上個月
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference.
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
正面
The Motley Fool
上個月
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
負面
Market Watch
上個月
20 stocks likely to lose money even if the bull market continues
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
20 stocks likely to lose money even if the bull market continues
正面
The Motley Fool
上個月
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
Analysts also raised their price targets on the company. On top of that, it launched a new round of capital raising.
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
查看新聞排名
價格圖表採用Lightweight Charts™實作